GNRH1 and primary ovarian failure: This study endorsed the role of ovarian function suppression with either tamoxifen or exemestane for patients at higher risk and noted the value of an LHRH agonist given during chemotherapy for premenopausal women with ER-negative disease in protecting against premature ovarian failure and preserving fertility [27].